Status:
COMPLETED
General Practice Research Database Seroquel XR Safety Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
University Hospital, Basel, Switzerland
Conditions:
Schizophrenia
Major Depressive Disorder
Eligibility:
All Genders
18-85 years
Brief Summary
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developin...
Detailed Description
Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.
Eligibility Criteria
Inclusion
- Episodes of new use (\>/=1 prescription) of quetiapine XR or other study drugs
Exclusion
- Less than two years of recorded history before the start of the marketing of quetiapine XR (or cohort entry date)
- If the duration and dose of the antipsychotic drug cannot be determined
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
37372 Patients enrolled
Trial Details
Trial ID
NCT01447082
Start Date
October 1 2008
End Date
December 1 2012
Last Update
February 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Switzerland